NCT03887026已完成2 期
Efficacy and Safety of Single Doses of Norketotifen in Adult Subjects With Allergen-Induced Allergic Rhinitis in an Allergen Challenge Chamber
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Change in Total Nasal Symptom Score (TNSS) from pre-dose to 6 hours post-dose
研究概览
简要总结
This is a Phase 2a study to evaluate the efficacy and safety of Norketotifen (NKT) in subjects with allergic rhinitis.
详细描述
This is a single-center, double-blind, randomized, placebo-controlled, 3-way crossover study evaluating the efficacy and safety of NKT in adult subjects with allergen-induced allergic rhinitis in an allergen challenge chamber.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability and willingness to provide informed consent and comply with the protocol procedures
- •Males and females, age 18 to 45 years, inclusive
- •Other than seasonal allergic rhinitis, participant is healthy as determined by pre-study medical history, physical examination and vital signs. Any chronic conditions that may interfere with the study outcomes or the subject's safety will be considered clinically significant and a reason for exclusion.
- •History of seasonal allergic rhinitis to mountain cedar pollen for at least the past 2 consecutive seasons
- •Positive mountain cedar pollen skin prick test at Screening or within 12 months prior to Screening (wheal diameter ≥5 mm larger than the negative control)
- •For females, negative serum pregnancy test. Females of childbearing potential and males must agree to use required contraception as outlined in the protocol
排除标准
- •Female subjects who are pregnant or lactating
- •Any history of epilepsy, diabetes mellitus, blood pressure abnormalities or cardiac arrhythmias
- •Presence of any uncontrolled medical or psychiatric illness
- •Treatment for controlled concurrent medical conditions has not been stable in terms of either doses or medications for at least 30 days prior to the baseline visit or is anticipated to change during the study
- •Current use of or expected use of any of the prohibited medications within the indicated withholding timeframes as outlined in the protocol
- •History of any illness that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the subject by their participation in the study
- •Any history of malignancy within the past 5 years, with the exception of non-melanoma skin cancer
- •History of pulmonary disease and/or active asthma requiring daily drug therapy. Mild, intermittent asthma is permitted (managed with short acting beta-agonist less than 3 times per week). Isolated exercise-induced bronchospasm is also permitted
- •Any infection or inflammatory condition within the 2 weeks prior to screening
- •Positive human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV) antibody screen
- •Any clinically significant abnormal laboratory or ECG test. Presence of thrombocytopenia at screening is exclusionary
- •Evidence of illicit drug use or positive urine Class A drug, alcohol, or cotinine screen
- •Regular use of tobacco or nicotine containing products, including vaping, within 1 year prior to Screening
- •Received any investigational drug within 30 days prior to Screening
- •Any prior exposure to norketotifen
- •History of allergic reaction to ketotifen
- •In the opinion of the investigator, subject would be unlikely to comply with required study visits, self-assessments, and interventions
研究组 & 干预措施
NKT Low Dose
Experimental
NKT single dose - Low
干预措施: Norketotifen (Drug)
NKT High Dose
Experimental
NKT single dose - High
干预措施: Norketotifen (Drug)
Placebo
Placebo Comparator
Placebo single dose
干预措施: Placebo (Drug)
结局指标
主要结局
Change in Total Nasal Symptom Score (TNSS) from pre-dose to 6 hours post-dose
时间窗: 6 hours
Change in TNSS from pre-dose to 6 hours post-dose for NKT vs placebo. The TNSS is the sum of the scores of four nasal symptoms (runny nose, congestion, itching, and sneezing) each scored on a scale of 0 to 3 (0=absent; 1=mild; 2=moderate; 3=severe). The TNSS score ranges from 0 to 12.
次要结局
- Change in Total Ocular Symptom Score (TOSS) from pre-dose to 6 hours post-dose(6 hours)
- Change in individual nasal symptoms from pre-dose to 6 hours post-dose(6 hours)
- Change in individual ocular symptoms from pre-dose to 6 hours post-dose(6 hours)
- AUC of TSS over 6 hours post-dose(6 hours)
- Change in Total Symptom Score (TSS) from pre-dose to 6 hours post-dose(6 hours)
- Area under the curve (AUC) of TNSS over 6 hours post-dose(6 hours)
- AUC of TOSS over 6 hours post-dose(6 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD)Sickle Cell DiseaseNCT01783691NKT Therapeutics21
已完成
1 期
A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic DermatitisHealthyAtopic DermatitisAsthmaNCT02345928Janssen Research & Development, LLC108
已完成
2 期
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)Leukemia, Lymphocytic, ChronicNCT00055146Eisai Inc.41
Unknown
1 期
CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal AdenocarcinomaPancreatic CancerNCT05052567Qilu Pharmaceutical Co., Ltd.50
已完成
2 期
Nitric Oxide Releasing Sinus Irrigation (NOSi) to Treat Recalcitrant Chronic Rhinosinusitis (RCRS)Chronic SinusitisNCT04163978Sanotize Research and Development corp.56